XML 206 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Equity
12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Equity Equity
Preferred stock: We have authorized 25 million shares of $0.01 par value preferred stock, none of which were issued or outstanding at December 31, 2022 and 2021.
Treasury stock: On September 26, 2022, the Board of Directors terminated the stock repurchase program it had previously authorized on October 22, 2018, which permitted us to purchase up to 8 million of our outstanding shares of common stock from November 5, 2018 through December 31, 2023. As of the date of termination, the 2018 repurchase program had approximately 3.8 million shares of common stock remaining for repurchase.
On September 26, 2022, the Board of Directors contemporaneously approved a new stock repurchase program to authorize us to purchase up to 6 million shares of our outstanding common stock from September 26, 2022 through December 31, 2025. We may repurchase shares from time to time in the open market, in privately negotiated transactions, or otherwise, at prices we deem appropriate. We are not obligated to repurchase any shares under the authorization, and the new repurchase program may be suspended, discontinued or modified at any time, for any reason and without notice. The parameters of our stock repurchase program are not established solely with reference to the dilutive impact of shares issued
under our stock incentive plan. However, we expect that, over time, share repurchases will offset the dilutive impact of shares issued under the stock incentive plan.
During 2022, we repurchased 1,283 thousand shares of common stock in open market transactions at a net cost of $112 million. During 2021, we repurchased 765 thousand shares of common stock in open market transactions at a net cost of $68 million.
Set forth below is a reconciliation of common stock share activity for 2022, 2021 and 2020:
(Shares of common stock, in thousands)IssuedHeld in TreasuryOutstanding
Balance at December 31, 201977,81110,99366,818
Issuance of restricted stock units as compensation(69)69
Performance shares and other share-based awards(5)5
Stock options exercised(124)124
Purchase/acquisition of treasury stock
Balance at December 31, 202077,81110,79567,016
Issuance of restricted stock units as compensation(69)69
Performance shares and other share-based awards(6)6
Stock options exercised(331)331
Purchase/acquisition of treasury stock765(765)
Balance at December 31, 202177,81111,15466,657
Issuance of restricted stock units as compensation(95)95
Performance shares and other share-based awards(43)43
Stock options exercised(182)182
Purchase/acquisition of treasury stock1,283(1,283)
Balance at December 31, 202277,81112,11765,694
Share-based payments: The following table summarizes the components of our share-based compensation expense for 2022, 2021 and 2020:
(in millions)202220212020
Stock options:
Pre-tax compensation expense$$$
Income tax benefit— — — 
Stock option expense, net of income taxes
Restricted stock units ("RSUs"):
Pre-tax compensation expense13 12 12 
Income tax benefit(1)(1)(1)
RSUs, net of income taxes12 11 11 
Performance shares and other share-based awards:
Pre-tax compensation expense12 
Income tax benefit(1)(1)(1)
Performance shares and other share-based compensation expense, net of income taxes11 
Total share-based compensation:
Pre-tax compensation expense29 23 23 
Income tax benefit(2)(2)(2)
Total share-based compensation expense, net of income taxes$27 $21 $21 
We have a stock incentive plan (“SIP”) administered by the People, Culture and Compensation Committee (“Compensation Committee”) of our Board of Directors that provides for the granting of stock options, restricted stock, restricted stock units and other share-based awards to certain key employees. A maximum of 8 million shares were originally authorized for awards under the SIP. On May 19, 2021, our stockholders approved an increase in the number of shares then available under the SIP by 2.5 million shares. As of December 31, 2022, 3.1 million shares were available for future grants under the SIP. Shares covered by awards that expire, terminate or lapse will again be available for the grant of awards under the SIP.
Stock Options: Under the SIP, stock options are granted at exercise prices that equal the market value of the underlying common stock on the date of grant. The options have a 10-year term and are exercisable upon vesting, which occurs over a three-year period at the anniversary dates of the date of grant.
We granted non-qualified options to purchase 281 thousand, 358 thousand and 336 thousand shares for 2022, 2021 and 2020, respectively. The fair value of each option grant was estimated using the Black-Scholes option-pricing model with the following assumptions:
For the Year Ended December 31,
202220212020
Expected life (in years)5.55.55.5
Risk-free interest rate2.0 %0.6 %1.4 %
Expected volatility23.8 %23.2 %19.8 %
Expected dividend yield2.9 %2.9 %2.9 %
The expected life of options represents the weighted average period that we expect options granted to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the grant date for the period corresponding to the expected life of the
options. Expected volatility is based on historical volatilities of our common stock, and dividend yields are based on our dividend yield at the date of issuance.
A summary of stock option transactions in 2022 is as follows:
Number of Options
(in thousands)
Weighted Average Exercise Price per ShareAverage Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in millions)
Outstanding as of December 31, 20212,154$90.39 5.26$26 
Granted28188.66 
Exercised(182)61.90 
Cancelled(31)103.55 
Outstanding as of December 31, 20222,222$92.32 5.16$24 
Exercisable as of December 31, 20221,651$93.79 4.03$18 
For 2022, 2021 and 2020, cash received from the exercise of stock options was $11 million, $21 million and $6 million, respectively. As of December 31, 2022, the unrecognized compensation cost related to non-vested stock options totaled $3 million, which is expected to be amortized over the weighted-average period of approximately 1.7 years.
Additional information pertaining to stock option activity is as follows:
Year Ended December 31,
(dollars in millions, except per share)202220212020
Weighted average grant date fair value of stock options granted (per share)$15.04 $12.31 $11.48 
Total intrinsic value of stock options exercised10 
Restricted Stock Units: We have granted restricted stock units (“RSUs”) to certain key employees. The RSUs are primarily subject to cliff vesting, generally after three years, provided the employee remains in our service. The fair value of the RSUs is determined based upon the number of shares granted and the quoted market price of our common stock at the grant date.
The following table summarizes RSU activity in 2022:
(shares in thousands)Number of
Restricted
Shares
Weighted
Average
Fair Value
per Share
Non-vested at December 31, 2021486$88.34 
Granted21388.80 
Vested(132)90.74 
Cancelled(50)87.14 
Non-vested at December 31, 2022517$88.04 
The total fair value of RSUs that vested in 2022, 2021 and 2020 was $12 million, $12 million and $17 million, respectively.
At December 31, 2022, the total remaining unrecognized compensation cost related to RSUs was $17 million, which will be amortized on a weighted-average basis over approximately 1.7 years. Recognized compensation cost related to unvested RSUs is included in Share-based payments subject to redemption in the Consolidated Balance Sheets and totaled $28 million and $25 million at December 31, 2022 and 2021, respectively.
Performance Shares: We have a long-term incentive plan for senior management in the form of performance shares. The vesting of the performance shares is generally based on two performance metrics. Fifty percent of the
performance shares awarded vest based on our total shareholder return as compared to the total shareholder return of our peer group and the remaining fifty percent vest based on the calculation of our three-year average Adjusted Return on Invested Capital (“ROIC”) against an established ROIC target. The 2021 performance shares were granted in two tranches. Vesting for the first tranche was split evenly between our total shareholder return and Adjusted ROIC against the applicable target. The second tranche of performance share awards vest 100 percent based on the calculation of Adjusted ROIC against the applicable target.
For the 2022 performance shares awarded based on our total shareholder return, the number of shares that ultimately vest can range from zero to 200 percent of the grant depending on our total shareholder return as compared to the total shareholder return of our peer group. The share award vesting will be calculated at the end of the three-year period and is subject to approval by management and the Compensation Committee of the Board of Directors. Compensation expense is based on the fair value of the performance shares at the grant date, established using a Monte Carlo simulation model. The total compensation expense for these awards is amortized over a three-year graded vesting schedule.
For the 2022 performance shares awarded based on Adjusted ROIC, the number of shares that ultimately vest can range from zero to 200 percent of the grant depending on our Adjusted ROIC performance against the target. The share award vesting will be calculated at the end of the three-year period and is subject to approval by management and the Compensation Committee. Compensation expense is based on the market price of our common stock on the grant date and the final number of shares that ultimately vest. We estimate the potential share vesting at least annually to adjust the compensation expense for these awards over the vesting period to reflect our estimated Adjusted ROIC performance against the target. The total compensation expense for these awards is amortized over a three-year graded vesting schedule.
We awarded 86 thousand, 108 thousand and 81 thousand performance shares in 2022, 2021 and 2020, respectively. The weighted average fair value of the shares granted during 2022, 2021 and 2020 was $138.85, $100.29 and $94.48, respectively.
The 2019 performance share awards that vested during 2022 achieved a zero percent payout of the granted performance shares. As of December 31, 2022, the 2020 performance share awards are estimated to pay out at 75 percent. Additionally, there were two thousand shares cancelled during 2022.
As of December 31, 2022, the unrecognized compensation cost relating to these plans was $8 million, which will be amortized over the remaining requisite service periods of 1.7 years. Recognized compensation cost related to these unvested awards is included in Share-based payments subject to redemption in the Consolidated Balance Sheets and totaled $20 million and $11 million at December 31, 2022 and 2021, respectively.
Other share-based awards under the SIP: Under the compensation agreement with the Board of Directors, $150,000 of a non-employee director’s annual retainer and 50 percent of the additional retainers paid to the lead director and the chairs of committees of the Board of Directors are awarded in shares of common stock or, if a director elects to defer all or a portion of the director's common stock or cash compensation, in shares of restricted stock units. These restricted units may not be transferred until a date not less than six months after the director’s termination of service from the Board of Directors, at which time the restricted units will be settled by delivering shares of common stock with fractional shares to be paid in cash. The compensation expense relating to this plan included in the Consolidated Statements of Income was approximately $2 million in each of 2022, 2021, and 2020. At December 31, 2022, there were approximately 230 thousand restricted stock units outstanding under this plan at a carrying value of approximately $15 million.
Accumulated Other Comprehensive Loss: A summary of accumulated other comprehensive income (loss) for 2022, 2021 and 2020, is presented below:
(in millions)Cumulative Translation AdjustmentHedging ActivitiesPension and Postretirement AdjustmentAOCL
Balance, December 31, 2019$(1,089)$(9)$(60)$(1,158)
Other comprehensive (loss) income before reclassification adjustments (25)(2)(22)
Loss reclassified from accumulated other comprehensive loss— 65 — 65 
Tax (provision) benefit— (19)(18)
Net other comprehensive (loss) income(25)51 (1)25 
Balance, December 31, 2020(1,114)42 (61)(1,133)
Other comprehensive (loss) income before reclassification adjustments (100)218 28 146 
Loss (gain) reclassified from accumulated other comprehensive loss311 (209)— 102 
Tax (provision)— (3)(9)(12)
Net other comprehensive income211 19 236 
Balance, December 31, 2021(903)48 (42)(897)
Other comprehensive (loss) gain before reclassification adjustments (105)210 (5)100 
(Gain) loss reclassified from accumulated other comprehensive loss— (268)— (268)
Tax benefit— 16 17 
Net other comprehensive income(105)(42)(4)(151)
Balance, December 31, 2022$(1,008)$$(46)$(1,048)
Supplemental Information: The following table provides the computation of basic and diluted earnings per common share (“EPS”) for the periods presented.
202220212020
(in millions, except per share amounts)Net Income
Available
to Ingredion
Weighted
Average
Shares
Per
Share
Amount
Net Income
Available
to Ingredion
Weighted
Average
Shares
Per
Share
Amount
Net Income
Available
to Ingredion
Weighted
Average
Shares
Per
Share
Amount
Basic EPS$492 66.2$7.43 $117 67.1$1.74 $348 67.2$5.18 
Effect of Dilutive Securities:
Incremental shares from assumed exercise of dilutive stock options and vesting of dilutive RSUs and other awards0.80.70.4
Diluted EPS$492 67.0$7.34 $117 67.8$1.73 $348 67.6$5.15 
Approximately 1.4 million, 0.9 million and 1.7 million share-based awards of common stock were excluded for 2022, 2021 and 2020, respectively, from the calculation of the weighted average number of shares outstanding for diluted EPS because their effects were anti-dilutive.